AgomAb Therapeutics (NASDAQ:AGMB) Director Buys $88,800.00 in Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 21st. The shares were purchased at an average price of $8.88 per share, for a total transaction of $88,800.00. Following the transaction, the director owned 25,000 shares of the company’s stock, valued at $222,000. This trade represents a 66.67% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

AgomAb Therapeutics Stock Down 2.3%

NASDAQ AGMB opened at $9.05 on Friday. The stock has a 50-day moving average of $11.52 and a 200 day moving average of $11.75. AgomAb Therapeutics NV has a twelve month low of $7.92 and a twelve month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Analysts predict that AgomAb Therapeutics NV will post -1.77 earnings per share for the current year.

Trending Headlines about AgomAb Therapeutics

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: Director David Epstein purchased 10,000 AGMB shares at an average price of $8.88, investing approximately $88,800 and increasing his direct ownership by 66.7% to 25,000 shares. Insider buying can signal management confidence that the stock is undervalued. AgomAb Therapeutics Director Buys 10,000 Shares
• Positive Sentiment: HC Wainwright raised its EPS forecasts for every year from fiscal 2026 through fiscal 2030. The revisions were modest but consistently favorable, with estimated losses narrowing to $1.91 per share in 2026, $2.02 in 2027, $1.75 in 2028, $1.81 in 2029 and $1.79 in 2030. The firm maintained its “Buy” rating.
• Neutral Sentiment: Analyst sentiment remains broadly constructive, with the company described as having a “Moderate Buy” consensus and several firms maintaining Buy or Overweight ratings. However, one research firm recently downgraded the shares to Sell, highlighting disagreement about the company’s outlook.
• Negative Sentiment: AgomAb is still expected to report losses, including a consensus estimate of approximately $1.83 in negative EPS for the current year. As a clinical-stage biotechnology company, its valuation remains dependent on progress in programs such as AGMB-129, while the shares continue to trade below their key moving averages.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AGMB. Wall Street Zen downgraded shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday. Johnson Rice reissued a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday. Piper Sandler began coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating on the stock. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.